Informuta

Thrilled to celebrate an amazing female founder, Kalen Hall, PhD, who I had the privilege of meeting this past spring! She's just been selected to represent TiE Houston in Bangalore! Her company, Informuta, is on a mission to revolutionize infectious disease detection and enable precision medicine for infections. They harness the power of AI and machine learning to analyze DNA through next-generation sequencing (NGS) data. Their novel, proprietary technology allows them to predict if bacteria will respond to different antibiotics or develop resistance over time—addressing the global health crisis of antibiotic resistance and saving lives by conserving current market-approved antibiotics. This is a powerful example of how AI and machine learning can be used for good to transform our world. Can't wait to see her continue to make an impact—congratulations on this well-deserved recognition! #FemaleFounder #AIForGood #MachineLearning #HealthcareInnovation #TiEHouston #PrecisionMedicine #WomenInTech #InspiringLeaders

Thrilled to finally publicly announce that I am going to Bangalore, India in December to pitch Informuta & compete on a global stage as a finalist for TiE Women TiE Global! We’ve been very grateful for our stakeholders in Houston since competing at RBPC, and I’m honored to be representing TiE Houston. Had a great time in Houston at the TiE Women Showcase this past week. Huge thank you to Carolyn Matula, Cindy L. Boyd, Smriti Agrawal, Ph.D., Mitra Miller for helping me for the past couple of months prepare for this and to and all of the leads & judges (Ashima Arora, Wendy Rentschler, & Pooja Revanur) for believing in me & Informuta’s mission. Congrats to the other semi-finalists Tanu J. and Vinita Gupta! & a special thank you to Amir Eskafyan for being an incredible champion & everything he does for women founders!

We’re so excited to have Edwin Solares join our team as our first Machine Learning Engineer! Edwin’s extensive experience in AI/ML, bioinformatics, and analyzing DNA sequencing data will be pivotal in furthering our product development and technology. Welcome Edwin!

Meet our next BioChallenge finalist, Informuta. Informuta is a cutting-edge biotech company competing in the 2024 BioChallenge, focused on tackling the global health crisis of antibiotic resistance. Leveraging its proprietary RESISENSE™ platform, powered by next-generation sequencing (NGS) and machine learning, Informuta predicts both current antibiotic resistance and future resistance acquisition with unprecedented accuracy. This precision medicine approach can revolutionize infectious disease detection and treatment, offering life-saving insights to healthcare providers. Informuta's participation in the BioChallenge could unlock significant funding, helping further their mission to combat the rise of antibiotic-resistant infections globally. Join us the morning of October 31st for a BioChallenge watch party to see their pitch: https://bit.ly/4eymm5p

Honored to have been selected for a podium talk @ ASM NGS 2024 this past weekend! Thank you to the organizers for the opportunity to share some recent exciting results from our work at Informuta and Tulane University School of Medicine. It was so exciting to hear recent developments in the field - it’s clear that sequencing is the future for infectious diseases!

Announcing the six finalists for the 2024 BioChallenge pitch competition, presented by Silicon Valley Bank! These innovative startups — Vocxi Health, SiVEC Biotechnologies, Anvil Diagnostics, Informuta, Vaxess Technologies, and EriVan Bio — are developing groundbreaking health security solutions. More: https://bit.ly/47Uej0G Join us on October 31st at the New Orleans BioInnovation Center for a watch party, where the audience will decide their own winner! Register: https://bit.ly/3XnubVV #HealthSecurity #BiotechInnovation #NewOrleans

We are proud to announce that Informuta has been accepted into the CDL - Seattle Computational Health program! Creative Destruction Lab CDL-Seattle We are ecstatic to participate in this program & grow as founders, grow as a venture, and #BuildSomethingMassive. Creative Destruction Lab (CDL) is a nonprofit organization that delivers an objectives-based program for massively scalable, seed-stage, science- and technology-based companies. Its nine-month program allows founders to learn from experienced entrepreneurs, increasing their likelihood of success. Founded by Professor Ajay Agrawal in 2012 at the University of Toronto's Rotman School of Management, the program has expanded to 11 sites across seven countries: Seattle, Paris, Madison, Vancouver, Calgary, Montreal, Halifax, Berlin, Estonia, and Melbourne. The successful commercialization of cutting-edge science and technology achieved through the program has led to the creation of over $37 billion in equity value.

Proud to announce the 2024 TiE Women Houston semi-finalists! FlowCare™ - founder Tanu Jain, MBA, BSN-RN Informuta- founder Kalen Hall, PhD Journ- founder Sara Shah Mar de Fondos- founder Montserrat Rodriguez TerraSolve Technologies- founder Vinita Gupta Rx Cranial Solutions- founder Kai Watson Wellness Surge- founder Adeola Oke, BSN, PharmD, MPH, BCPS Join us on October 23rd at Ion Houston to meet the semi-finalists and hear who will be representing TiE Houston at TiE Global Summit this year. Thank you to our Houston co-leads Ashima Arora, Pooja Revanur, and Wendy Rentschler

Fundraising is a critical task for start up companies. On this week’s episode of #RevealingLi, I talk with Dr. Kalen Hall, PhD and CEO of Informuta about the fundraising process and what she has learned along the way. #womenleaders #womenfounders #womenintechnology #AI #machinelearning P19 Leveraging Machine Learning in the Fight Against Antibiotic Resistance with Dr. Kalen Hall is available now on: Apple Podcasts https://lnkd.in/gvK9bUHv Spotify https://lnkd.in/g8JWva_4 Amazon Music https://lnkd.in/gwEsQEpa Audible https://lnkd.in/gBQxERvC

Informuta was awarded a Phase I STTR grant from the National Science Foundation for $275,000 aimed to expand our covered species and perform clinical validation in partnership with University of Pittsburgh Medical Center. https://lnkd.in/gx69VYPi